Last reviewed · How we verify
ICP-192
At a glance
| Generic name | ICP-192 |
|---|---|
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer (PHASE2)
- A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma (PHASE2)
- A Study of ICP-192 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations (PHASE2)
- Clinical Study of ICP-192 in Solid Tumors Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICP-192 CI brief — competitive landscape report
- ICP-192 updates RSS · CI watch RSS
- Beijing InnoCare Pharma Tech Co., Ltd. portfolio CI